Artificial intelligence news and machine learning news

News and Trends 24 Jan 2023

CytoReason expands deal with Sanofi to look at IBD

CytoReason, which creates computational disease modeling, has announced an expansion of its collaboration with Sanofi. The multi-year collaboration will further fuel Sanofi’s target discovery efforts via CytoReason’s AI platform in the field of inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets. In 2021, Cytoreason announced the initiation of a […]

January 24, 2023 - 2 minutesmins - By Jim Cornall

Interview 19 Jan 2023

Interview: Proscia talks about digital pathology

Labiotech recently interviewed Nathan Buchbinder, chief product officer at Proscia, about digital pathology. AI has been a hot topic in drug discovery. Can you outline how it’s being applied to pathology data? Sure, it’s always great to start with such an exciting topic! There are two broad applications of AI that I want to highlight. […]

January 19, 2023 - 8 minutesmins - By Jim Cornall

News and Trends 12 Jan 2023

Beyond Biotech podcast 29: Janssen, Knowledge Gate

This week, our guests are Viktoriya Vasilenko, Knowledge Gate co-founder and CEO; and Avery Ince, vice president, medical affairs, cardiovascular & metabolism at Janssen Scientific Affairs, LLC. Study confirms benefit of XARELTO (rivaroxaban) for secondary prevention of venous thromboembolism in cancer patients The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed observational data from […]

January 12, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Jan 2023

What’s in store for biotech in 2023?

Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […]

January 11, 2023 - 14 minutesmins - By Jim Cornall

News and Trends 21 Dec 2022

Poolbeg identifies new potential drug candidates for RSV infections

Poolbeg Pharma says it has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) program with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked with OneThree to build a tailored AI approach that leverages Poolbeg’s RSV human challenge trial data to identify […]

December 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Cyclica and SK Chemicals to co-develop novel therapeutics

Cyclica Inc. and SK Chemicals Co., Ltd. have announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas. Under this collaboration, Cyclica will deploy its proprietary drug discovery platforms to identify novel drug candidates for challenging biological targets across therapeutic areas of mutual interest to both companies. SK […]

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

Etcembly reveals breakthrough in optimizing TCR assets

Etcembly has announced the successful prediction and optimization of multiple T cell receptor (TCR) assets for targeting leukemias and solid tumors. The company’s machine learning platform EMLy (Etcembly machine learning) enables AI based engineering of novel TCRs from the complete theoretical TCR repertoire. The unification of machine-learning-based optimization with empirical validation has facilitated the rapid […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

PhoreMost and ThinkCyte collaborate on AI-based drug discovery

PhoreMost Ltd. and ThinkCyte K.K have announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI). The partnership leverages both companies’ technologies in high-throughput drug discovery. These are PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterization and sorting platform, Ghost Cytometry. The aim is to develop […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

Opinion 12 Dec 2022

Artificial intelligence: a new era in rare genetic disease diagnosis

Despite the onset of the genomics era, rare disease diagnosis remains a challenge. Nostos Genomics’ co-founder, Rocío Acuña Hidalgo, and chief operating officer, Ansgar Lange, shed light on how artificial intelligence (AI) could fill in the gaps. It is estimated that 300 million people worldwide are affected by rare diseases and around 80% of these […]

December 12, 2022 - 6 minutesmins - By External Contributor

News and Trends 9 Dec 2022

Vevo Therapeutics launches with $12M to ‘discover better drugs’

Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, has launched with an oversubscribed and upsized $12 million seed financing round. Wing Venture Capital and General Catalyst co-led the round with participation from Mubadala Capital, AIX Ventures, and Camford […]

December 9, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Ibex and Source announce agreement to aid pathologists with diagnostic accuracy

An agreement has been announced between Ibex Medical Analytics and Source LDPath, part of Source BioScience. It will expand the deployment of artificial intelligence (AI) to Source’s entire pathology network. Ibex works with AI-powered cancer diagnostics and the expansion builds on its previous work with LDPath. Source, which provides integrated laboratory services and products, acquired […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 6 Dec 2022

Tetra announce significant results from the study of Onternabez combined with Favipiravir

Tetra Bio-Pharma Inc. a leader in cannabinoid-derived drug discovery and development announced today significant results from the study of Onternabez combined with Favipiravir. The combination acts against ARDS (acute respiratory distress syndrome), Sepsis, and Covid-19 through PREPAiRE, an artificial intelligence (AI) powered platform. The platform, the companies say, purposely integrates target identification, validation, lead discovery […]

December 6, 2022 - 2 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us